Enhancer of Zeste Homolog 2 Silences MicroRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin
Chi Han Li(Chinese University of Hong Kong), Yangchao Chen(Guangzhou University of Chinese Medicine), Ka‐Fai To(Chinese University of Hong Kong), Yinxin Zhu(Chinese University of Hong Kong), Zhangang Xiao(Southwest Medical University), Tian Xia(Huazhong Agricultural University), Víctor E. Márquez(Hospital la Serena), Joanna Hung‐Man Tong(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Sheung Ching Chow(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong)
Cited by 62
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k